Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1419-1428

  Sunwoo, John B ^a   Chen, Zhong ^a   Dong, Gang ^a   Yeh, Ning ^a   Bancroft, Caren Crowl ^a   Sausville, Edward ^b   Adams, Julian ^c   Elliott, Peter ^c   Van Waes, Carter ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; MULTIENZYME COMPLEXES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034902354     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Constitutive activation of transcription factors NF-(κ)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines
2. The nuclear factor-κ B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
3. The NF-κ B transcription factor and cancer: High expression of NF-κ B- and I κ B-related proteins in tumor cell lines
4. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth
5. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer
6. Constitutive activation of NF-κB in primary adult T-cell leukemia cells
7. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
8. The host environment promotes the constitutive activation of nuclear factor-κB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma
9. Growth-regulated oncoprotein-α expression by murine squamous-cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration, and angiogenesis by a host CXC receptor-2-dependent mechanism
10. Expression of a dominant-negative mutant inhibitor κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo
11. Activation in vitro of NF-κ B by phosphorylation of its inhibitor I κ B
12. The ubiquitin-proteasome pathway is required for processing the NF-κ B1 precursor protein and the activation of NF-κ B
13. A proteasome inhibitor prevents activation of NF-κ B and stabilizes a newly phosphorylated form of I κB-α that is still bound to NF-κ B
14. The NF-κ B and Iκ B proteins: New discoveries and insights
15. Proteasome inhibitors: A novel class of potent and effective antitumor agents
16. The proteasome inhibitor PS-341 in cancer therapy
17. A survey of transformation markers in differentiating epidermal cell lines in culture
18. Metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous-cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction
19. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma
20. Human squamous-cell carcinoma. Establishment and characterization of new permanent cell lines
21. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
22. Evidence in support of a role for human T-cell leukemia virus type I Tax in activating NF-κ B via stimulation of signaling pathways
23. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis
24. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
25. Cleavage of poly(ADP-ribose) polymerase: A sensitive parameter to study cell death
26. The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1α, IL-6, GM-CSF, and KC
27. How NF-κB is activated: The role of the IκB kinase (IKK) complex
28. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
29. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-l to preferentially suppress chemotherapy-induced apoptosis
30. The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications
31. Constitutive NF-κB activity regulates growth, angiogenesis, and metastasis of cutaneous human melanoma
32. Proteasome inhibitor PS-341 effective as an anti-angiogenic agent in the treatment of human pancreatic carcinoma via the inhibition of NF-κB and subsequent inhibition of vascular endothelial growth factor production
33. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
34. Control of inducible chemoresistance: Enhanced antitumor therapy through increased apoptosis by inhibition of NF-κB